Adoptive cell therapy is undergoing a decisive transition from hematological malignancies into the biologically complex landscape of solid tumors through multifaceted cellular engineering and multimodal combination regimens. In a comprehensive review published in Experimental Hematology & Oncology, researchers led by Peng Huang, WenLin Wu, Yu Min, and Xingchen Peng systematically evaluate the historical trajectory, present breakthroughs, and engineering frontiers of immune-cell transfer platforms. While adoptive cell therapies have delivered revolutionary, durable remissions in blood cancers such as relapsed B-cell acute lymphoblastic leukemia and lymphomas, solid malignancies continue to present severe physical and immunological hurdles. These hostile barriers include a dense extracellular matrix, abnormal tumor vasculature, mismatched chemokine gradients, rapid T-cell exhaustion under chronic antigenic stimulation, target antigen heterogeneity, and a profoundly immunosuppressive tumor microenvironment populated by regulatory factors and myeloid-derived suppressor cells. To circumvent these constraints, investigators are expanding beyond conventional autologous alpha-beta T cells by introducing synthetic gene circuits, targeted gene editing, non-viral delivery systems, and alternative innate immune effector lineages.
The engineering of chimeric antigen receptor T-cell therapies exemplifies this technological evolution, progressing across five generations from rudimentary activation modules to highly responsive cellular systems. Early first-generation constructs pairing a single-chain variable fragment to an isolated CD3-zeta domain permitted target recognition but suffered from inadequate cytokine secretion and poor in vivo persistence. Subsequent clinical approvals in hematological diseases were driven by second- and third-generation architectures that incorporated CD28 or 4-1BB co-stimulatory domains to bolster proliferation and cellular survival. Fourth-generation armored designs, known as T cells redirected for universal cytokine-mediated killing, incorporate inducible or constitutive cassettes for cytokines such as interleukin-12, interleukin-15, or interleukin-18 to counteract local immunosuppression. Fifth-generation architectures integrate truncated cytokine receptor chains with STAT3 or STAT5 signaling domains to engage intracellular JAK-STAT cascades upon direct antigen engagement. Researchers emphasize that choosing between integrating lentiviral or retroviral vectors for permanent receptor expression and transient approaches, such as messenger RNA electroporation or lipid nanoparticles, depends on balancing the need for long-term antitumor surveillance against the hazards of prolonged on-target, off-tumor toxicities.
Clinical trials in solid malignancies are beginning to provide randomized and prospective evidence validating these targeted CAR-T modalities in specific tumor types. In gastric and gastroesophageal junction cancers expressing Claudin 18.2, the autologous CAR-T candidate satricabtagene autoleucel achieved a statistically significant prolongation of median progression-free survival in the randomized phase II CT041-ST-01 trial, reaching 3.25 months compared with 1.77 months under physician’s choice treatment. The objective response rate reached approximately 22 percent versus 4 percent in the control arm, with median overall survival extending from 5.49 months to 7.92 months. Toxicities were dominated by low-grade cytokine release syndrome without observed immune effector cell-associated neurotoxicity syndrome. In advanced hepatocellular carcinoma, therapies targeting glypican-3 have demonstrated encouraging clinical activity, particularly when engineered with cytokine payloads or dominant-negative transforming growth factor-beta receptor II. The C-CAR031 construct, built to withstand suppressive TGF-beta signaling, generated an objective response rate of 44.4 percent and a median overall survival of 14.2 months in a first-in-human trial of 36 patients, demonstrating how microenvironment-adapted modifications directly protect effector cell function against systemic immunosuppression.
Beyond conventional alpha-beta T lymphocytes, emerging adoptive cellular platforms are leveraging innate immune effectors such as macrophages, natural killer cells, and natural killer T cells to exploit distinct immunological properties. Chimeric antigen receptor macrophages represent an attractive modality for solid tumors because monocytes and macrophages naturally home into tumor tissue and display intrinsic phagocytic activity. In a phase I clinical evaluation of the HER2-directed CAR-macrophage CT-0508 in advanced solid tumors, treatment demonstrated a favorable safety profile without dose-limiting toxicities, inducing stable disease in four of fourteen evaluated patients alongside enhanced intratumoral CD3-positive and CD8-positive T-cell infiltration and upregulation of activation markers such as CD68 and HLA-DR. Similarly, CAR-engineered natural killer cells offer reduced risk of graft-versus-host disease and lower incidences of severe cytokine release syndrome, making them prime candidates for centralized, off-the-shelf cell banking. Invariant natural killer T cells, which utilize semi-invariant T-cell receptors restricted by CD1d rather than polymorphic human leukocyte antigens, can directly eradicate immunosuppressive tumor-associated macrophages and myeloid-derived suppressor cells while preserving broad cytotoxicity.
Unmodified and genetically tuned tumor-infiltrating lymphocytes represent another clinically validated modality, achieving a landmark milestone in 2024 with the accelerated regulatory approval of lifileucel for advanced melanoma. Tumor-infiltrating lymphocyte therapy relies on resecting autologous tumor fragments, isolating endogenous reactive clones, and performing rapid expansion protocols with high-dose interleukin-2 and irradiated feeder cells following lymphodepleting chemotherapy. Because these cellular mixtures comprise polyclonal populations directed against diverse tumor-associated antigens and private somatic neoantigens, they naturally mitigate the risk of single-antigen immune escape. Clinical data demonstrate sustained overall response rates of 31 percent in pivotal phase II trials of pretreated metastatic melanoma, with preliminary efficacy extending into non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical malignancies. Nevertheless, broader clinical implementation remains hindered by variable expansion efficiency, loss of fitness, and terminal exhaustion within suppressive microenvironments, prompting ongoing investigations into single-cell profiling, defined phenotypic subpopulation selection, and intracellular checkpoint disruption using CRISPR-mediated ablation of regulators such as CISH.
Engineered T-cell receptor therapies complement CAR approaches by extending target recognition beyond surface-bound proteins to intracellular tumor proteins presented as peptide-major histocompatibility complexes. Because single peptide-MHC complexes can initiate productive immunological synapses, TCR-T interventions demonstrate exquisite sensitivity to low-copy-number intracellular antigens. The field reached an important milestone in 2024 with the regulatory approval of afamitresgene autoleucel for synovial sarcoma targeting MAGE-A4, supported by an objective response rate of 39 percent in clinical cohorts. Additional clinical investigations targeting cancer-testis antigens, viral oncoproteins derived from human papillomavirus or hepatitis B virus, and recurrent somatic driver mutations in KRAS, TP53, and PIK3CA demonstrate expanding scope. To enhance persistence and overcome functional exhaustion, investigators are evaluating combinations with lymph node-targeting nanoparticulate peptide vaccines and CRISPR-Cas9-mediated replacement of endogenous T-cell receptors, which reduces unwanted hybrid TCR pairing while preserving central memory phenotypes and durable in vivo fitness.
Therapeutic cancer vaccines represent a parallel adoptive immunotherapy paradigm aimed at activating endogenous immune responses through dendritic cells, synthetic peptides, or mRNA-based formulations. Dendritic cells function as master antigen-presenting cells capable of acquiring tumor-associated antigens or patient-specific neoantigens and presenting them via MHC molecules to prime native cytotoxic T lymphocytes. Autologous dendritic cell platforms loaded with tumor lysates, defined peptides, or electroporated messenger RNA have demonstrated tangible clinical utility across multiple malignancies, including castration-resistant prostate cancer, glioblastoma, and melanoma. In newly diagnosed glioblastoma, the addition of the lysate-loaded dendritic cell vaccine DCVax-L to standard temozolomide chemotherapy extended median overall survival to 19.3 months compared with 16.5 months in standard cohorts, while the double-loading DOC1021 platform combining tumor lysates and amplified mRNA showed promising recurrence-free survival improvements in resected pancreatic ductal adenocarcinoma. In parallel, B-cell peptide vaccines targeting receptor tyrosine kinases such as HER2 or the PD-1 axis are emerging to induce endogenous polyclonal antibodies, demonstrating clinical safety and expanding multimodal immune modulation.
Given the multi-layered defenses established by solid tumors, single-agent adoptive cell therapies rarely achieve permanent disease eradication, driving widespread exploration of rational combination regimens. Preconditioning or concurrent administration of conventional chemotherapy and radiotherapy can induce immunogenic cell death, releasing damage-associated molecular patterns and tumor neoantigens that stimulate host antigen-presenting cells and promote epitope spreading. Radiation also remodels tumor vasculature, upregulates cell adhesion molecules and chemokine gradients, and promotes local CAR-T infiltration, as shown in preclinical CLDN18.2 models where localized radiation induced sustained CCL2 production and systemic regression. Pairing adoptive cell therapies with immune checkpoint inhibitors, such as programmed cell death protein 1 or programmed death-ligand 1 antagonists, counters progressive effector exhaustion and restores cytokine secretion within chronically inflamed lesions. Early trials combining mesothelin-directed CAR-T cells with pembrolizumab in malignant pleural mesothelioma achieved a median overall survival of 23.9 months, although responses across diverse solid tumors remain contingent on baseline PD-L1 expression, tumor immunogenicity, and individual microenvironmental composition.
Synthetic biology and precision genome engineering are delivering programmable control mechanisms to heighten safety, tumor selectivity, and metabolic fitness during cellular trafficking. Boolean logic systems such as synthetic Notch circuits require dual antigen recognition, compelling effector cells to express therapeutic receptors only upon encountering specific priming signals within the tumor parenchyma, thereby sparing healthy tissues that express low levels of target antigens. Environmental gating systems incorporate hypoxia-inducible degradation domains to confine CAR expression to low-oxygen tumor niches, a design validated in 2026 phase I trials of the CEA-directed PC13 CAR-T product, which met its primary safety endpoints in heavily pretreated cancer patients. At the metabolic level, genetic overexpression of PGC-1alpha variants and CRISPR-directed screens targeting proline metabolism have revealed actionable pathways to reinforce mitochondrial biogenesis, sustain bioenergetic reserve, and mitigate metabolic exhaustion within nutrient-depleted, hypoxic tumor beds.
Transforming these intricate cellular technologies into widely accessible therapies demands substantial advances in biomanufacturing scalability, quality assurance, and adaptive regulatory frameworks. Current autologous cell therapies require complex vein-to-vein workflows spanning four to six weeks for leukapheresis, ex vivo genetic transduction, expansive culture, and rigorous release testing, creating logistical hurdles for rapidly progressing solid cancer patients. Developing scalable allogeneic platforms using healthy donor cells, umbilical cord blood, or induced pluripotent stem cells offers a pathway toward banked, off-the-shelf therapeutic products, provided that alloreactivity, graft-versus-host disease, and host-mediated graft rejection are effectively suppressed through multiplex gene editing. Regulatory agencies emphasize comprehensive lifecycle process control, validated potency assays reflecting multifaceted biological mechanisms, and rigorous monitoring for insertional mutagenesis or secondary malignancies. By unifying targeted synthetic gene circuits, rational combination modalities, and standardized manufacturing platforms, researchers are systematically dismantling the biological defenses of solid tumors to deliver durable therapeutic responses.
Subject of Research: Engineering strategies and translational progress of adoptive cell therapies for solid malignancies
Article Title: Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation
Article References: Huang, P., Wu, W., Min, Y., Zhang, Y., Tao, Y., Liu, Z., Wei, Z., & Peng, X. (2026). Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation. Experimental Hematology & Oncology, 15(1), Article 109. https://doi.org/10.1186/s40164-026-00848-3
Image Credits: AI Generated
DOI: 10.1186/s40164-026-00848-3
Keywords: Adoptive cell therapy, Solid tumors, CAR-T therapy, TCR-T therapy, Tumor-infiltrating lymphocytes, CAR-macrophages, CAR-NK cells, CAR-NKT cells, Dendritic cell vaccines, Tumor microenvironment, Synthetic gene circuits, CRISPR gene editing, Lifileucel, Afamitresgene autoleucel, Satricabtagene autoleucel, Lipid nanoparticles, Immune checkpoint inhibitors
News Source: Juliet Wilcox. (November 17, 2026). Adoptive Cell Therapies Advance Against Solid Tumors Through Multi-Layered Cellular Engineering. Scienmag.



